Study of Ataluren (PTC124) in Cystic Fibrosis

PHASE3TerminatedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

May 23, 2014

Primary Completion Date

June 5, 2017

Study Completion Date

June 5, 2017

Conditions
Cystic Fibrosis
Interventions
DRUG

Ataluren

Ataluren will be administered per dose and schedule specified in the arm.

Trial Locations (17)

10003

Beth Israel Medical Center, New York

31059

Hôpital des Enfants, Toulouse

35233

University of Alabama-Birmingham, Birmingham

44106

Rainbow Babies & Children's Hospital, Cleveland

60614

Children's Hospital Chicago, Chicago

80045

Denver Children's Hospital, Aurora

90806

Miller Children's Hospital Long Beach, Long Beach

91240

Hadassah University Hospital - Mount Scopus, Jerusalem

02115

Children's Hospital Boston, Boston

Unknown

Hôpital Universitaire des Enfants Reine Fabiola, Brussels

University Hospital Brussels, Brussels

University Hospital Leuven, Leuven

Hôpital Necker - Enfants Malades, Paris

Università La Sapienza, Roma

Azienda Ospedaliera di Verona, Verona

Hospital Universitario La Paz, Madrid

Karolinska University Hospital, Huddinge, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY

NCT02107859 - Study of Ataluren (PTC124) in Cystic Fibrosis | Biotech Hunter | Biotech Hunter